Guardant Health, Inc. (GH) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $127.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 10%; Below-average business quality; Rich valuation.
Guardant Health develops blood and tissue precision oncology tests for therapy selection, minimal residual disease monitoring, and colorectal cancer screening in the United States. Tests drove 94% of 2025 revenue, alongside biopharmaceutical collaborations; the company posted a... Read more
Sell if holding. Engine safety override at $127.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 10%; Below-average business quality; Rich valuation. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 42d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
About Guardant Health, Inc.
About Guardant Health, Inc.
Guardant360 CDx, the first FDA-approved liquid biopsy test for solid tumor mutation profiling and companion diagnostic use, and Shield, the first blood-based test approved for primary colorectal cancer screening and meeting Medicare coverage requirements, anchor Guardant Health's commercial portfolio. Tests represented 94% of total revenue in both 2024 and 2025, with biopharmaceutical collaborations making up the remainder. The company reported net losses of $416.3 million in 2025 against an accumulated deficit of $3.0 billion at year-end.
Guardant Health sells tests to oncologists, cancer centers, primary care physicians, and health systems through a U.S. direct sales force, and to biopharmaceutical companies for companion diagnostic development, retrospective testing, and clinical study enrollment. Clinical test revenue is subject to negotiated rates from contracted commercial payers and to variable reimbursement from non-contracted payers, which set their own rates and may retroactively recover prior payments — a pattern that has already occurred. Medicare accounted for more than 10% of total revenue in each of 2025, 2024, and 2023, and Guardant Health depends on a CMS laboratory date-of-service exception to bill Medicare directly in certain settings. Top-five biopharmaceutical customers contributed 11% of total revenue in 2025, down from 14% in 2023. Competition in liquid biopsy therapy selection includes Foundation Medicine (acquired by Roche), Caris Life Sciences, and Tempus AI; GRAIL and Exact Sciences compete in early cancer detection.
Show full overview
Guardant Health's Medicare revenue — representing more than 10% of total revenue — exposes the company to CMS policy risk: if CMS repeals or curtails the laboratory date-of-service exception that allows molecular pathology labs to bill Medicare directly, revenue could materially decrease. Commercial payer risk compounds this exposure; non-contracted payers retain the right to retroactively review and recover prior payments, a risk that has already materialized and that could cause quarterly results to fall below guidance.
See also: Healthcare · Diagnostics & Research
From Guardant Health, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-06-17Recent Developments — Guardant Health, Inc.
Latest news
- NEWS RBC Capital Initiates Coverage On Guardant Health with Outperform Rating, Announces Price Target of $185 — benzinga Jun 12, 2026 positive
- NEWS Guardant Health Says FDA Approves Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim's HERNEXEOS — benzinga Jun 11, 2026 positive
- NEWS Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $175 — benzinga Jun 8, 2026 positive
- NEWS Goldman Sachs Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $165 — benzinga Jun 5, 2026 positive
- NEWS CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga Jun 2, 2026 neutral
Generated 2026-06-17T11:26:49Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProducttests94%10-K Item 1A: 'our tests, which accounted for 94%, 94% and 91% of our revenue in the years ended December 31, 2025, 2024 and 2023, respectively'
- LOWCustomerMedicare10-K Item 1A: 'Revenue attributable to Medicare accounted for more than 10% of our total revenue in each of the years ended December 31, 2025, 2024 and 2023'
- LOWCustomertop five biopharmaceutical customers11%10-K Item 1A: 'revenue from our top five biopharmaceutical customers, including their affiliated entities, accounted for 11%, 13% and 14% of our total revenue, respectively'
Material Events(8-K, last 90d)
- 2026-04-27Item 5.02MEDIUMCraig Eagle, M.D., Chief Medical Officer, resigned effective May 8, 2026. No successor named. No reason cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -40.1%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $127.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: High short interest: 10%; Below-average business quality; Rich valuation. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $118.43. Score 5.3/10, moderate confidence.
Take-profit target: $132.30 (+3.9% upside). Prior stop was $118.43. Stop-loss: $118.43.
Concentration risk — Product: tests (94.0%); Target reached (-0.4% upside); Quality below floor (3.7 < 4.0).
Guardant Health, Inc. trades at a P/E of N/A (forward -238.9). TrendMatrix value score: 2.4/10. Verdict: Sell.
32 analysts cover GH with a consensus score of 4.3/5. Average price target: $141.
What does Guardant Health, Inc. do?Guardant Health develops blood and tissue precision oncology tests for therapy selection, minimal residual disease...
Guardant Health develops blood and tissue precision oncology tests for therapy selection, minimal residual disease monitoring, and colorectal cancer screening in the United States. Tests drove 94% of 2025 revenue, alongside biopharmaceutical collaborations; the company posted a net loss of $416.3 million in 2025. Shield is the first FDA-approved blood test for primary colorectal cancer screening and meets Medicare coverage requirements.